Medulloblastoma in adults

Medulloblastoma in adults Strahlenther Onkol (2018) 194:225–234 https://doi.org/10.1007/s00066-017-1235-5 ORIGINAL ARTICLE A retrospective single institution analysis 1 1 1 1,2 3,4,5 Indrawati Hadi · Olarn Roengvoraphoj · Maximilian Niyazi · Falk Roeder · Ulrich Schüller · 1,6 1 Claus Belka · Silke Birgit Nachbichler Received: 31 July 2017 / Accepted: 26 October 2017 / Published online: 16 November 2017 © Springer-Verlag GmbH Deutschland 2017 Abstract tients. The most common side effects were hematologi- Purpose Adult medulloblastoma is a rare disease treated cal toxicities. Median overall survival (OS) has not been according to the current pediatric treatment guidelines. This reached after a median follow-up of 92 months. Estimated retrospective analysis investigated the clinical outcomes and 5- and 10-year OS was 89 and 80%, respectively. Estimated prognostic factors of adult medulloblastoma patients, who 5- and 10-year progression-free survival (PFS) was 89 and received multimodal therapy at our institution. 81%, respectively. In univariate analysis, a shorter interval Methods Treatment charts of all patients over the age of between tumor resection and end of irradiation was signif- 15 years of age with de novo medulloblastoma, who had icantly associated with improved OS and PFS, anaplastic been treated at our institution between 2001 and 2014, histology with worse http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Strahlentherapie und Onkologie Springer Journals
Loading next page...
 
/lp/springer_journal/medulloblastoma-in-adults-PZ0M16EUdl
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Deutschland
Subject
Medicine & Public Health; Radiotherapy; Oncology
ISSN
0179-7158
eISSN
1439-099X
D.O.I.
10.1007/s00066-017-1235-5
Publisher site
See Article on Publisher Site

Abstract

Strahlenther Onkol (2018) 194:225–234 https://doi.org/10.1007/s00066-017-1235-5 ORIGINAL ARTICLE A retrospective single institution analysis 1 1 1 1,2 3,4,5 Indrawati Hadi · Olarn Roengvoraphoj · Maximilian Niyazi · Falk Roeder · Ulrich Schüller · 1,6 1 Claus Belka · Silke Birgit Nachbichler Received: 31 July 2017 / Accepted: 26 October 2017 / Published online: 16 November 2017 © Springer-Verlag GmbH Deutschland 2017 Abstract tients. The most common side effects were hematologi- Purpose Adult medulloblastoma is a rare disease treated cal toxicities. Median overall survival (OS) has not been according to the current pediatric treatment guidelines. This reached after a median follow-up of 92 months. Estimated retrospective analysis investigated the clinical outcomes and 5- and 10-year OS was 89 and 80%, respectively. Estimated prognostic factors of adult medulloblastoma patients, who 5- and 10-year progression-free survival (PFS) was 89 and received multimodal therapy at our institution. 81%, respectively. In univariate analysis, a shorter interval Methods Treatment charts of all patients over the age of between tumor resection and end of irradiation was signif- 15 years of age with de novo medulloblastoma, who had icantly associated with improved OS and PFS, anaplastic been treated at our institution between 2001 and 2014, histology with worse

Journal

Strahlentherapie und OnkologieSpringer Journals

Published: Nov 16, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off